Located in Irvine, California, CombriMatrix has quickly earned reputation as a molecular diagnostics company that performs DNA-based testing services for cancer and developmental disorders. Today, CombiMatrix took a major step towards prominence with the announcement that industry veteran Jeff Haynes has been named Director of Sales for the Oncology market.
Hayes is a renowned name within the sector and has over two decades of experience in the sector. Jeff Hayes has held an array of positions which stem from marketing management positions with Schering-Plough and Eli Lilly to sales management roles with US LABS and PLUS Diagnostics.
Leading the team at CombiMatrix is Judd Jessup whom serves as President and CEO. In reference to the addition of Jeff Hayes, Jessup stated, “Growing our cancer diagnostics business and list of clients is a key attribute of our strategy and will be an important revenue driver in the coming years. Having worked with Jeff in the past, I have first-hand knowledge of his skill and professional sales aptitude, especially when it comes to introducing new cancer testing services. I am certain that he is the right choice for this important role.”
ConbiMatrix has developed a unique approach to analyzing a patient’s cancer which provides both prognostic and therapeutic information by analyzing hundreds of key OncoGenes at once with personalized state-of-the-art results. To enhance the value of the company, Hayes will be heading the sales efforts of CombiMatrix’s DNAarray test portfolio which include DNAarray Heme Profile, the DNAarray Tumor Profile and the DNAarray Breast Profile.
Currently, CombiMatrix is trading in the $2.54 range. To learn more about this press release or the company as a whole, visit their corporate website at: www.combimatrix.com
Let us hear your thoughts below: